Dynavax Technologies Corporation reaffirmed revenue guidance for the year 2023. The company is reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165$185 million, representing annual revenue growth of 30%-47%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11 USD | -0.27% | -6.46% | -21.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.32% | 1.44B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023